A. Kolnagou

发表

New targeted therapies and diagnostic methods for iron overload diseases.

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2018, Frontiers in bioscience.

Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2013, Expert opinion on investigational drugs.

Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

G. Kontoghiorghes, A. Kolnagou, M. Kleanthous, 2010, European journal of haematology.

The molecular spectrum and distribution of haemoglobinopathies in Cyprus: a 20-year retrospective study

M. Angastiniotis, G. Christopoulos, T. Papasavva, 2016, Scientific Reports.

Long Term Comparative Studies in Thalassemia Patients Treated with Deferoxamine or a Deferoxamine/Deferiprone Combination. Identification of Effective Chelation Therapy Protocols

E. Eracleous, G. Kontoghiorghes, A. Kolnagou, 2008, Hemoglobin.

Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone

K. Kyriacou, Christos Kontos, G. Kontoghiorghes, 2008, Hemoglobin.

Dietary and pharmacological factors affecting iron absorption in mice and man (Comment for a Letter to the editor)

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2016, Haematologica.

Interactions Of Hydroxycarbamide (Hydroxyurea) With Iron And Copper: Implications On Toxicity and Therapeutic Strategies

G. Kontoghiorghes, I. Pashalidis, A. Kolnagou, 2011, Hemoglobin.

Chelators Controlling Metal Metabolism and Toxicity Pathways: Applications in Cancer Prevention, Diagnosis and Treatment

G. Kontoghiorghes, A. Kolnagou, Aglaia Efstathiou, 2008, Hemoglobin.

The Scope for Thalassemia Gene Therapy by Disruption of Aberrant Regulatory Elements

T. Cathomen, C. Mussolino, M. Antoniou, 2019, Journal of clinical medicine.

Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease.

G. Kontoghiorghes, A. Kolnagou, Marios Kleanthous, 2022, Frontiers in bioscience.

The Role of Iron and Chelators on Infections in Iron Overload and Non Iron Loaded Conditions: Prospects for the Design of New Antimicrobial Therapies

G. Petrikkos, A. Skiada, G. Kontoghiorghes, 2010, Hemoglobin.

Maintenance of Normal Range Body Iron Store Levels for up to 4.5 Years in Thalassemia Major Patients Using Deferiprone Monotherapy

G. Kontoghiorghes, A. Kolnagou, 2010, Hemoglobin.

The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.

G. Kontoghiorghes, A. Kolnagou, K. Pattichis, 2004, Current medicinal chemistry.

Chelation protocols for the elimination and prevention of iron overload in thalassaemia.

G. Kontoghiorghes, A. Kolnagou, 2018, Frontiers in bioscience.

Antioxidant targeting by deferiprone in diseases related to oxidative damage.

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2014, Frontiers in bioscience.

Effective Combination Therapy of Deferiprone and deferoxamine for the Rapid Clearance of Excess Cardiac IRON and the Prevention of Heart Disease in Thalassemia. The Protocol of the International Committee on Oral Chelators

G. Kontoghiorghes, A. Kolnagou, 2006, Hemoglobin.

Low Serum Ferritin Levels are Misleading for Detecting Cardiac Iron Overload and Increase the Risk of Cardiomyopathy in Thalassemia Patients. The Importance of Cardiac Iron Overload Monitoring Using Magnetic Resonance Imaging T2 and T2*

E. Eracleous, G. Kontoghiorghes, A. Kolnagou, 2006, Hemoglobin.

Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

G. Kontoghiorghes, A. Kolnagou, C. Fessas, 2004, British journal of haematology.

Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions

G. Kontoghiorghes, A. Kolnagou, K. Neocleous, 2003, Drug safety.

Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*

G. Kontoghiorghes, A. Kolnagou, K. Natsiopoulos, 2013, Toxicology mechanisms and methods.

The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2013, Toxicology mechanisms and methods.

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.

E. Eracleous, G. Kontoghiorghes, A. Kolnagou, 2005, Current medicinal chemistry.

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).

G. Kontoghiorghes, A. Kolnagou, M. Hadjigavriel, 2000, Transfusion science.

Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.

G. Kontoghiorghes, A. Kolnagou, 2006, Haematologica.

Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2015, Molecules.

New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications

G. Kontoghiorghes, A. Kolnagou, Theodora Demetriou, 2021, International journal of molecular sciences.

Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications

G. Kontoghiorghes, N. Polyakov, C. Kontoghiorghe, 2020, Medicines.

Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases

S. Shah, G. Kontoghiorghes, A. Aessopos, 2010, Expert opinion on drug safety.

Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2017, Drug Research.

Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2014, World journal of methodology.

Efficacy, Compliance And Toxicity Factors Are Affecting The Rate Of Normalization Of Body Iron Stores In Thalassemia Patients Using The Deferiprone And Deferoxamine Combination Therapy

G. Kontoghiorghes, A. Kolnagou, Marios Kleanthous, 2011, Hemoglobin.

New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores

G. Kontoghiorghes, A. Kolnagou, 2010, British journal of haematology.

Iron Chelation Therapy in Hereditary Hemochromatosis and Thalassemia Intermedia: Regulatory and Non Regulatory Mechanisms of Increased Iron Absorption

G. Kontoghiorghes, George J Kontoghiorghes, Aspasia Spyrou, 2010, Hemoglobin.

Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.

G. Kontoghiorghes, A. Kolnagou, 2005, Current medicinal chemistry.

Conventional and Unconventional Approaches for Innovative Drug Treatments in COVID-19: Looking Outside of Plato’s Cave

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2021, International journal of molecular sciences.

Iron mobilisation from transferrin by deferiprone (L1)

E. Eracleous, R. W. Evans, A. Kolnagou, 2005, British journal of haematology.

Deferiprone for thalassaemia

A. Kolnagou, M. Agarwal, J. Marx, 2000, The Lancet.

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2017, Mediterranean journal of hematology and infectious diseases.

Hb Famagusta—analysis of a novel δ-globin chain variant [HBD:c.60C>A] in four families with diverse globin genotypes

M. Kleanthous, C. Lederer, A. Kolnagou, 2014, Annals of Hematology.

Effects on Mycobacterium avium Replication in Normal Human Macrophages by Deferiprone (L1) and Other Iron Chelators

G. Kontoghiorghes, A. Kolnagou, M. May, 2002, Arzneimittelforschung.

EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment

T. Born, G. Kontoghiorghes, C. Kontoghiorghe, 2013, Toxicology mechanisms and methods.

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility

A. Kolnagou, G. Kontoghiorghes, 2003, The Lancet.

Hb A2 Episkopi – a novel δ-globin chain variant [HBD:c.428C>T] in a family of mixed Cypriot–Lebanese descent

C. Sismani, G. Tanteles, P. Evangelidou, 2017, Hematology.

Post COVID-19 Reflections and Questions: How Prepared Are We for the Next Pandemic?

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2024, International journal of molecular sciences.

Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2013, Expert opinion on investigational drugs.